When and how to use mood stabilizers during breastfeeding

Area of Science:

• Perinatology
• Psychiatry
• Pharmacology

Background:

• Postpartum mood stabilizers are crucial for women with bipolar disorder to prevent recurrence of depression, mania, or psychosis.
• Breastfeeding during this period exposes infants to these medications, requiring careful consideration.

Purpose of the Study:

• To review the risks and benefits of untreated mental illness, breastfeeding, and mood stabilizer exposure for mothers and infants.
• To summarize available data on drug concentrations, adverse events, and limitations for informed clinical decision-making.

Main Methods:

• Review of literature on mood stabilizer use during breastfeeding.
• Summary of reported breast milk and infant serum drug concentrations.
• Description of adverse events associated with lithium, valproate, and carbamazepine.

Main Results:

• Data on drug concentrations in breast milk and infant serum are summarized.
• Adverse events for specific mood stabilizers (lithium, valproate, carbamazepine) are detailed.
• Limitations of current data are highlighted to aid risk assessment.

Conclusions:

• A thorough risk-benefit analysis is essential for deciding on breastfeeding while using mood stabilizers.
• Physicians can use summarized data to better assess risks and benefits for individual patients.
• Practical recommendations are provided to guide clinical practice regarding mood stabilizer use during breastfeeding.